Product Description: Sotiburafusp alfa is a bispecific fusion protein, which is a humanized VEGFR-1 extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker 101GGSGGSGGSGGSGGS115 to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human PD-L1 heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor[1].
Applications: Neuroscience-Neuromodulation
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 4, 2022.
CAS Number: 2637466-37-4
Molecular Weight: N/A
Research Area: Cardiovascular Disease
Solubility: H2O
Target: PD-1/PD-L1;VEGFR